US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Therapeutics

29.73

-0.7300-2.40%

Volume:708.67K

Turnover:21.80M

Market Cap:847.96M

PE:-15.66

High:32.00

Open:30.84

Low:29.55

Close:30.46

52wk High:50.40

52wk Low:16.54

Shares:28.52M

Float Shares:25.04M

Volume Ratio:0.78

T/O Rate:2.83%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-1.8984

EPS(LYR):-2.3387

ROE:-26.25%

ROA:-18.44%

PB:4.11

PE(LYR):-12.71

Loading ...

Overview Company News Filings

Press Release: Plus Therapeutics Updates on CNSide(R) Diagnostic Platform Launch

Summit Therapeutics price target raised to $16 from $13 at Barclays

JW Therapeutics Advances SLE Treatment with Promising Phase I Results

Neurizon Therapeutics Secures Australian Patent Covering NUZ-001 Drug Candidate for Neurodegenerative Disease Treatment

MT Newswires Live

SpringWorks Therapeutics Announces Publication of Long-Term Efficacy and Safety Data from the Phase 3 DeFi Trial of OGSIVEO® (nirogacestat) in Adults with Desmoid Tumors in the Journal of Clinical Oncology

SpringWorks Therapeutics Announces Publication of Long-Term Efficacy and Safety Data from the Phase 3 DeFi Trial of OGSIVEO® (nirogacestat) in Adults with Desmoid Tumors in the Journal of Clinical Oncology

Alterity Therapeutics Announces 2025 Annual General Meeting

PYC Therapeutics Launches Global Repeat Dose Study of Eye Disease Drug Candidate

MT Newswires Live

Major Stakeholder Sells Millions in LAVA Therapeutics Stock!

PYC Therapeutics Launches Global Trial for ADOA Treatment

Arovella Therapeutics Showcases iNKT Cell Therapy at AusBiotech Invest 2025

Tryptamine Therapeutics to Present at Microcap Investment Conference

Neuphoria Therapeutics Ends SAD Program After Trial Failure

Pliant Therapeutics Settles Loan with Oxford Finance

Rapt Therapeutics Raised to Overweight From Neutral by JP Morgan

Rapt Therapeutics price target raised to $60 from $41 at Clear Street

Neuphoria Therapeutics Provides Update on AFFIRM-1 Phase 3 Trial Evaluating BNC210 for the Acute Treatment of Social Anxiety Disorder

Summit Therapeutics Launches New Phase III Study

Viridian Therapeutics Secures $300M Deal with DRI Healthcare

Adaptimmune Therapeutics to Delist from Nasdaq by October 27

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/LENZ/news?page=10"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"LENZ","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LENZ\",,,,,undefined,":{"symbol":"LENZ","market":"US","secType":"STK","nameCN":"Therapeutics","latestPrice":29.73,"timestamp":1761940703047,"preClose":30.46,"halted":0,"volume":708673,"delay":0,"floatShares":25041690,"shares":28522100,"eps":-1.898372,"marketStatus":"Trading","change":-0.73,"latestTime":"10-31 15:58:23 EDT","open":30.84,"high":32,"low":29.55,"amount":21798219.502311,"amplitude":0.080433,"askPrice":29.76,"askSize":113,"bidPrice":29.73,"bidSize":400,"shortable":3,"etf":0,"ttmEps":-1.898372,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1761940800000},"marketStatusCode":2,"adr":0,"listingDate":1624593600000,"exchange":"NASDAQ","adjPreClose":30.46,"preHourTrading":{"tag":"盘前","latestPrice":31.07,"preClose":30.46,"latestTime":"09:13 EDT","volume":887,"amount":27355.888944,"timestamp":1761916410636},"postHourTrading":{"tag":"盘后","latestPrice":30.46,"preClose":30.46,"latestTime":"19:18 EDT","volume":10198,"amount":310772.4,"timestamp":1761866309733},"volumeRatio":0.78477,"impliedVol":1.2232,"impliedVolPercentile":0.986},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LENZ\",,,,,undefined,":{"symbol":"LENZ","floatShares":25041690,"roa":"-18.44%","roe":"-26.25%","lyrEps":-2.338654,"volumeRatio":0.78477,"shares":28522100,"dividePrice":0,"high":32,"amplitude":0.080433,"preClose":30.46,"low":29.55,"week52Low":16.535,"pbRate":"4.11","psRate":"169.59","week52High":50.4,"institutionHeld":0,"latestPrice":29.73,"committee":0.559454,"eps":-1.898372,"divideRate":0,"volume":708673,"delay":0,"ttmEps":-1.898372,"open":30.84,"prevYearClose":28.87,"prevWeekClose":31.97,"prevMonthClose":46.58,"prevQuarterClose":46.58,"fiveDayClose":31.97,"twentyDayClose":48.74,"sixtyDayClose":32.12,"earningDate":1762272000000,"earningTime":"盘前"},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LENZ\",params:#limit:5,,,undefined,":[{"date":"2025-11-05","symbol":"LENZ","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":"2025/09","expectedEps":-0.67,"defaultRemindTime":1762333200000,"name":null,"time":"Pre-Market","dateTimestamp":1762318800000,"actualEps":null},{"market":"US","date":"2025-07-30","symbol":"LENZ","fiscalQuarterEnding":"2025/06","expectedEps":-0.58,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1753848000000,"reportTimeType":"pre","actualEps":-0.53},{"market":"US","date":"2024-05-08","symbol":"LENZ","fiscalQuarterEnding":"2024/03","expectedEps":-0.84,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1715140800000,"reportTimeType":"pre","actualEps":-3.53},{"market":"US","date":"2024-03-22","symbol":"LENZ","defaultRemindTime":1711114200000,"type":"split","dateTimestamp":1711080000000,"forFactor":7,"toFactor":1,"ratio":7},{"date":"2024-03-22","symbol":"LENZ","amount":1.03,"announcedDate":null,"type":"dividend","market":"US","newRecordDate":"2024-03-18","name":"Therapeutics","recordDate":"2024-03-21","payableDate":"2024-03-18","currency":"USD","dateTimestamp":1711080000000,"payDate":"2024-03-21"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LENZ\",market:\"US\",,,undefined,":[{"executeDate":"2024-03-22","recordDate":"2024-03-18","paymentDate":"2024-03-21","value":1.03,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LENZ\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.5,"buy":0.5,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.5,"analysts":8,"updateTime":1742270400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/LENZ\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"LENZ","date":"2025-10-30","current":-15.955777,"percent":0.360313,"low":-26.69966,"twenty":-17.694227,"median":-12.203976,"eighty":-8.163327,"high":-5.069183,"avg":-13.19362,"sd":5.357781,"marketCap":820338875},"quantilePoints":[{"date":"2024-03-28","current":-7.959158,"twenty":-7.219077,"median":-6.108955,"eighty":-6.016992,"marketCap":556886354},{"date":"2024-04-05","current":-7.492045,"twenty":-7.873034,"median":-7.667213,"eighty":-6.662191,"marketCap":524203432},{"date":"2024-04-12","current":-7.929963,"twenty":-7.855517,"median":-7.667213,"eighty":-7.432197,"marketCap":554843672},{"date":"2024-04-19","current":-6.382653,"twenty":-7.855517,"median":-7.488396,"eighty":-6.783348,"marketCap":446581492},{"date":"2024-04-26","current":-5.638193,"twenty":-7.716113,"median":-7.451903,"eighty":-5.889996,"marketCap":394493084},{"date":"2024-05-03","current":-5.988527,"twenty":-7.671592,"median":-6.864363,"eighty":-5.803142,"marketCap":419005276},{"date":"2024-05-10","current":-5.317808,"twenty":-7.667213,"median":-6.108955,"eighty":-5.803142,"marketCap":393230653},{"date":"2024-05-17","current":-5.708011,"twenty":-7.597146,"median":-6.0013,"eighty":-5.749862,"marketCap":422084590},{"date":"2024-05-24","current":-5.428308,"twenty":-7.489126,"median":-6.006774,"eighty":-5.719496,"marketCap":401401679},{"date":"2024-05-31","current":-5.355793,"twenty":-7.479638,"median":-5.988527,"eighty":-5.522773,"marketCap":396039443},{"date":"2024-06-07","current":-5.193496,"twenty":-7.457742,"median":-5.904593,"eighty":-5.428999,"marketCap":384038248},{"date":"2024-06-14","current":-6.433167,"twenty":-7.451903,"median":-5.930138,"eighty":-5.428308,"marketCap":475706952},{"date":"2024-06-21","current":-6.236339,"twenty":-7.425628,"median":-5.992177,"eighty":-5.43107,"marketCap":461152311},{"date":"2024-06-28","current":-6.150011,"twenty":-7.389135,"median":-6.0013,"eighty":-5.439358,"marketCap":454768696},{"date":"2024-07-05","current":-6.098214,"twenty":-7.269437,"median":-6.014073,"eighty":-5.469746,"marketCap":450938528},{"date":"2024-07-12","current":-6.771573,"twenty":-6.771573,"median":-6.098214,"eighty":-5.493918,"marketCap":500730721},{"date":"2024-07-15","current":-7.261916,"twenty":-7.163847,"median":-6.103393,"eighty":-5.509112,"marketCap":536989651},{"date":"2024-08-02","current":-8.498134,"twenty":-7.266429,"median":-6.108573,"eighty":-5.524305,"marketCap":628403011},{"date":"2024-08-09","current":-8.328931,"twenty":-7.474529,"median":-6.146558,"eighty":-5.597209,"marketCap":615891126},{"date":"2024-08-16","current":-8.944708,"twenty":-7.671592,"median":-6.236339,"eighty":-5.641258,"marketCap":621424629},{"date":"2024-08-23","current":-8.79431,"twenty":-7.94748,"median":-6.352018,"eighty":-5.670717,"marketCap":610975896},{"date":"2024-08-30","current":-8.746816,"twenty":-8.006409,"median":-6.382653,"eighty":-5.719496,"marketCap":607676296},{"date":"2024-09-06","current":-9.451311,"twenty":-8.199004,"median":-6.419354,"eighty":-5.743293,"marketCap":656620360},{"date":"2024-09-13","current":-8.17293,"twenty":-8.352945,"median":-6.434893,"eighty":-5.773217,"marketCap":567806132},{"date":"2024-09-20","current":-8.7389,"twenty":-8.507104,"median":-6.459289,"eighty":-5.788545,"marketCap":607126363},{"date":"2024-09-27","current":-8.806184,"twenty":-8.638371,"median":-6.616182,"eighty":-5.792924,"marketCap":611800796},{"date":"2024-10-04","current":-8.897214,"twenty":-8.745233,"median":-7.269437,"eighty":-5.800953,"marketCap":618125029},{"date":"2024-10-11","current":-9.340491,"twenty":-8.850511,"median":-7.455552,"eighty":-5.81701,"marketCap":648921294},{"date":"2024-10-18","current":-10.417023,"twenty":-8.905129,"median":-7.492045,"eighty":-5.857882,"marketCap":723712222},{"date":"2024-10-25","current":-9.902504,"twenty":-9.0017,"median":-7.670862,"eighty":-5.904593,"marketCap":687966558},{"date":"2024-10-31","current":-10.939457,"twenty":-9.257377,"median":-7.718702,"eighty":-5.904593,"marketCap":760007820},{"date":"2024-11-08","current":-14.709443,"twenty":-9.419648,"median":-7.959158,"eighty":-5.955683,"marketCap":894466512},{"date":"2024-11-15","current":-15.344855,"twenty":-9.514636,"median":-8.00261,"eighty":-5.970448,"marketCap":933105265},{"date":"2024-11-22","current":-15.521232,"twenty":-9.76398,"median":-8.132103,"eighty":-5.988527,"marketCap":943830613},{"date":"2024-11-29","current":-16.100113,"twenty":-9.924668,"median":-8.17293,"eighty":-5.994366,"marketCap":979031755},{"date":"2024-12-06","current":-16.33076,"twenty":-10.388526,"median":-8.285117,"eighty":-6.004584,"marketCap":993057210},{"date":"2024-12-13","current":-13.920266,"twenty":-10.815972,"median":-8.351032,"eighty":-6.018452,"marketCap":846477455},{"date":"2024-12-20","current":-13.694141,"twenty":-11.182468,"median":-8.50374,"eighty":-6.082845,"marketCap":832727009},{"date":"2024-12-27","current":-14.476534,"twenty":-12.093039,"median":-8.531114,"eighty":-6.098214,"marketCap":880303552},{"date":"2025-01-03","current":-12.794163,"twenty":-13.449021,"median":-8.618187,"eighty":-6.102358,"marketCap":778000234},{"date":"2025-01-10","current":-11.912274,"twenty":-13.190334,"median":-8.707238,"eighty":-6.108649,"marketCap":724373495},{"date":"2025-01-17","current":-10.130408,"twenty":-13.019383,"median":-8.746816,"eighty":-6.115785,"marketCap":616019980},{"date":"2025-01-24","current":-11.197719,"twenty":-12.871045,"median":-8.79431,"eighty":-6.143105,"marketCap":680922085},{"date":"2025-01-31","current":-11.523339,"twenty":-12.794163,"median":-8.877425,"eighty":-6.150011,"marketCap":700722728},{"date":"2025-02-07","current":-12.070562,"twenty":-12.328345,"median":-8.905129,"eighty":-6.232886,"marketCap":733998807},{"date":"2025-02-14","current":-11.432889,"twenty":-12.292165,"median":-8.964497,"eighty":-6.236339,"marketCap":695222549},{"date":"2025-02-21","current":-11.279124,"twenty":-12.151063,"median":-8.998138,"eighty":-6.308164,"marketCap":685872246},{"date":"2025-02-28","current":-9.62841,"twenty":-12.079607,"median":-9.059485,"eighty":-6.342695,"marketCap":585493990},{"date":"2025-03-07","current":-10.297741,"twenty":-11.943932,"median":-9.320702,"eighty":-6.355126,"marketCap":626195310},{"date":"2025-03-14","current":-11.193196,"twenty":-11.879712,"median":-9.419648,"eighty":-6.365485,"marketCap":680647077},{"date":"2025-03-21","current":-14.554795,"twenty":-11.943932,"median":-9.482973,"eighty":-6.379634,"marketCap":724377586},{"date":"2025-03-28","current":-14.68208,"twenty":-12.421509,"median":-9.574004,"eighty":-6.398202,"marketCap":730712447},{"date":"2025-04-04","current":-12.728528,"twenty":-13.089934,"median":-9.668992,"eighty":-6.415901,"marketCap":633486102},{"date":"2025-04-11","current":-10.2603,"twenty":-12.90813,"median":-9.741473,"eighty":-6.42488,"marketCap":510644883},{"date":"2025-04-17","current":-12.761733,"twenty":-12.945214,"median":-9.779811,"eighty":-6.430405,"marketCap":635138674},{"date":"2025-04-25","current":-15.833323,"twenty":-13.271407,"median":-9.84549,"eighty":-6.435239,"marketCap":788008663},{"date":"2025-05-02","current":-15.982746,"twenty":-13.932929,"median":-9.940463,"eighty":-6.440764,"marketCap":795445305},{"date":"2025-05-09","current":-15.25222,"twenty":-14.136351,"median":-10.102399,"eighty":-6.452984,"marketCap":728141003},{"date":"2025-05-16","current":-16.118891,"twenty":-14.245886,"median":-10.138549,"eighty":-6.460191,"marketCap":769515850},{"date":"2025-05-23","current":-16.637714,"twenty":-14.356129,"median":-10.19625,"eighty":-6.460792,"marketCap":794284465},{"date":"2025-05-30","current":-17.410053,"twenty":-14.523491,"median":-10.236057,"eighty":-6.585104,"marketCap":831155927},{"date":"2025-06-06","current":-17.864023,"twenty":-14.65894,"median":-10.342966,"eighty":-6.96771,"marketCap":852828466},{"date":"2025-06-13","current":-17.439532,"twenty":-14.747436,"median":-10.384797,"eighty":-7.264924,"marketCap":832563235},{"date":"2025-06-20","current":-17.704839,"twenty":-14.88454,"median":-10.454615,"eighty":-7.299361,"marketCap":845229004},{"date":"2025-06-27","current":-17.752005,"twenty":-15.005667,"median":-10.623361,"eighty":-7.425628,"marketCap":847480696},{"date":"2025-07-03","current":-19.178768,"twenty":-15.33581,"median":-10.694071,"eighty":-7.451903,"marketCap":915594389},{"date":"2025-07-11","current":-20.198727,"twenty":-15.529319,"median":-10.766979,"eighty":-7.459202,"marketCap":964287236},{"date":"2025-07-18","current":-20.381494,"twenty":-15.833323,"median":-10.791578,"eighty":-7.484747,"marketCap":973012543},{"date":"2025-07-25","current":-19.691695,"twenty":-16.100113,"median":-11.044571,"eighty":-7.492045,"marketCap":940081543},{"date":"2025-08-01","current":-16.20487,"twenty":-16.158905,"median":-11.077981,"eighty":-7.667213,"marketCap":849102797},{"date":"2025-08-08","current":-17.484059,"twenty":-16.20487,"median":-11.141188,"eighty":-7.667213,"marketCap":916129723},{"date":"2025-08-15","current":-22.268769,"twenty":-16.33076,"median":-11.193196,"eighty":-7.674511,"marketCap":1166838947},{"date":"2025-08-22","current":-21.691773,"twenty":-16.434778,"median":-11.220775,"eighty":-7.693556,"marketCap":1136605525},{"date":"2025-08-29","current":-20.793619,"twenty":-16.611183,"median":-11.233899,"eighty":-7.743848,"marketCap":1089544067},{"date":"2025-09-05","current":-21.729877,"twenty":-16.749673,"median":-11.252126,"eighty":-7.89274,"marketCap":1138602072},{"date":"2025-09-12","current":-22.214335,"twenty":-16.928962,"median":-11.290275,"eighty":-7.953319,"marketCap":1163986737},{"date":"2025-09-19","current":-22.693351,"twenty":-17.073997,"median":-11.339198,"eighty":-7.982513,"marketCap":1189086182},{"date":"2025-09-26","current":-21.789753,"twenty":-17.210778,"median":-11.419321,"eighty":-7.998378,"marketCap":1141739502},{"date":"2025-10-03","current":-26.302295,"twenty":-17.347559,"median":-11.473592,"eighty":-8.003646,"marketCap":1378187678},{"date":"2025-10-10","current":-25.175521,"twenty":-17.497557,"median":-11.534645,"eighty":-8.0071,"marketCap":1319146940},{"date":"2025-10-17","current":-22.018374,"twenty":-17.690689,"median":-11.749464,"eighty":-8.107241,"marketCap":1153718783},{"date":"2025-10-24","current":-16.034033,"twenty":-17.707197,"median":-11.991418,"eighty":-8.145558,"marketCap":840151237},{"date":"2025-10-30","current":-15.65592,"twenty":-17.694227,"median":-12.203976,"eighty":-8.163327,"marketCap":820338875}],"updateTime":1761938789865},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LENZ\",pageSize:20,pageCount:10,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2577282400","title":"Press Release: Plus Therapeutics Updates on CNSide(R) Diagnostic Platform Launch","url":"https://stock-news.laohu8.com/highlight/detail?id=2577282400","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577282400?lang=en_us&edition=fundamental","pubTime":"2025-10-21 19:30","pubTimestamp":1761046200,"startTime":"0","endTime":"0","summary":"Appoints new leadership in commercial strategy and technical operations. HOUSTON, Oct. 21, 2025  -- Plus Therapeutics, Inc.  , a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system  cancers, announces continued operational execution and commercial progress in the launch of its wholly owned subsidiary, CNSide Diagnostic LLC's, Cerebrospinal Fluid  Tumor Cell Enumeration laboratory developed test .Recent accomplishments include expansion of the CNSide manufacturing footprint, advancements in commercial readiness and appointments in key leadership positions to propel the CNSide diagnostic business forward. To lead commercialization strategy, Russ Havranek, MS, MBA, has been promoted to Executive Vice President, Commercial and Corporate Strategy. In addition, Daniel Ortega, MBA, has been promoted to the position of Vice President, Development and Technical Operations to lead our diagnostic capabilities a","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","BK4232","BK4600","BK4596","BK4135","STRK","BK4516","BK4588","CNS","BK4023","CSF","PSTV","BK4595","BK4022","LENZ","BK4007","R","BK4585"],"gpt_icon":1},{"id":"2577823172","title":"Summit Therapeutics price target raised to $16 from $13 at Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2577823172","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577823172?lang=en_us&edition=fundamental","pubTime":"2025-10-21 17:40","pubTimestamp":1761039621,"startTime":"0","endTime":"0","summary":"Barclays raised the firm’s price target on Summit Therapeutics (SMMT) to $16 from $13 and keeps an Underweight rating on the shares. The firm updat...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/summit-therapeutics-price-target-raised-to-16-from-13-at-barclays-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/summit-therapeutics-price-target-raised-to-16-from-13-at-barclays-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","SMMF"],"gpt_icon":0},{"id":"2577840190","title":"JW Therapeutics Advances SLE Treatment with Promising Phase I Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2577840190","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577840190?lang=en_us&edition=fundamental","pubTime":"2025-10-21 16:37","pubTimestamp":1761035854,"startTime":"0","endTime":"0","summary":"JW (Cayman) Therapeutics Co. Ltd. ( ($HK:2126) ) just unveiled an update. JW Therapeutics has submitted Phase I study data of Relmacabtagene autole...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/jw-therapeutics-advances-sle-treatment-with-promising-phase-i-results?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/jw-therapeutics-advances-sle-treatment-with-promising-phase-i-results?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","SLE","LENZ","BK4007","BK4077","BK4139"],"gpt_icon":0},{"id":"2577846313","title":"Neurizon Therapeutics Secures Australian Patent Covering NUZ-001 Drug Candidate for Neurodegenerative Disease Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2577846313","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577846313?lang=en_us&edition=fundamental","pubTime":"2025-10-21 14:33","pubTimestamp":1761028406,"startTime":"0","endTime":"0","summary":"Neurizon Therapeutics  was told by the Australian Patent Office of the grant of a new method of use patent, which will extend protection for its NUZ-001 drug candidate and related compounds across key therapeutic areas, including mTOR-pathway related diseases, such as amyotrophic lateral sclerosis, and other neurodegenerative diseases, according to a Tuesday Australian bourse filing.The granted patent complements Neurizon's existing US patent for NUZ-001 in neurodegenerative diseases and cancer and gives the firm unified intellectual property protection through to May 2041 across major global markets, per the filing.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","XAO.AU","XKO.AU","BK7096","BK4007","NUZ.AU","BK4139","XJO.AU","BK4539"],"gpt_icon":0},{"id":"2577846438","title":"SpringWorks Therapeutics Announces Publication of Long-Term Efficacy and Safety Data from the Phase 3 DeFi Trial of OGSIVEO® (nirogacestat) in Adults with Desmoid Tumors in the Journal of Clinical Oncology","url":"https://stock-news.laohu8.com/highlight/detail?id=2577846438","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577846438?lang=en_us&edition=fundamental","pubTime":"2025-10-21 14:00","pubTimestamp":1761026400,"startTime":"0","endTime":"0","summary":"Long-term continuous OGSIVEO treatment for up to 4 years was associated with further tumor size reductions, increase in objective response rate, sustained improvement in desmoid tumor symptoms and con","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/21/3169927/0/en/SpringWorks-Therapeutics-Announces-Publication-of-Long-Term-Efficacy-and-Safety-Data-from-the-Phase-3-DeFi-Trial-of-OGSIVEO-nirogacestat-in-Adults-with-Desmoid-Tumors-in-the-Journa.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0070302665.USD","LU0211331839.USD","LU1069347547.HKD","BK4588","IE0009355771.USD","SG9999001176.USD","SG9999002232.USD","LU1989772923.USD","BK4139","BK4534","LU1917777945.USD","PFS","BK4559","LU1035773651.USD","LU0203347892.USD","PRO","SG9999001440.SGD","BK4007","LU2112291526.USD","LU0203345920.USD","BK4533","SG9999014559.SGD","IE00BBT3K403.USD","LU0965509283.SGD","IE00BFTCPJ56.SGD","LU0106261372.USD","LU1941712264.USD","SG9999002224.SGD","LU1093756168.USD","LU0965509101.SGD","LU1934455863.HKD","LU2023250843.SGD","MRK","LU1023059063.AUD","LU1929549753.HKD","LU1430594728.SGD","IE00B2B36J28.USD","BK4516","SG9999013999.USD","BK4585","ORR","LENZ","LU1983299246.USD","LU1066051225.USD","LU0122379950.USD","LU1974910355.USD","LU1066051498.USD","IE0002141913.USD","LU0289739699.SGD","LU0208291251.USD"],"gpt_icon":0},{"id":"2577464328","title":"SpringWorks Therapeutics Announces Publication of Long-Term Efficacy and Safety Data from the Phase 3 DeFi Trial of OGSIVEO® (nirogacestat) in Adults with Desmoid Tumors in the Journal of Clinical Oncology","url":"https://stock-news.laohu8.com/highlight/detail?id=2577464328","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577464328?lang=en_us&edition=fundamental","pubTime":"2025-10-21 14:00","pubTimestamp":1761026400,"startTime":"0","endTime":"0","summary":"– Long-term continuous OGSIVEO treatment for up to 4 years was associated with further tumor size reductions, increase in objective response rate, sustained improvement in desmoid tumor symptoms and c","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/21/3169940/0/en/SpringWorks-Therapeutics-Announces-Publication-of-Long-Term-Efficacy-and-Safety-Data-from-the-Phase-3-DeFi-Trial-of-OGSIVEO-nirogacestat-in-Adults-with-Desmoid-Tumors-in-the-Journa.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1291159041.SGD","LU1989772923.USD","BK4585","SG9999002232.USD","BK4007","IE00BSNM7G36.USD","LU1035773651.USD","LU0203347892.USD","LU1116320901.HKD","PFS","IE00BLSP4452.SGD","IE00BN8TJ469.HKD","LU2106854487.HKD","IE00B2B36J28.USD","SG9999015358.SGD","SG9999001176.SGD","IE0009355771.USD","LU0106261372.USD","IE00B4R5TH58.HKD","IE00B1BXHZ80.USD","LU1061106388.HKD","LU1941712348.USD","ORR","LU0266013472.USD","BK4195","SG9999014567.USD","LU0211331839.USD","LENZ","LU1066051225.USD","LU1585245621.USD","LU2023250843.SGD","MRK","SG9999013999.USD","LU2324357040.USD","SG9999014559.SGD","LU0098860793.USD","LU0965509101.SGD","LU1917777945.USD","LU1162221912.USD","LU0122379950.USD","LU1069347547.HKD","LU0203345920.USD","LU1430594728.SGD","IE00BBT3K403.USD","IE00BJJMRZ35.SGD","LU0320765489.SGD","BK4023","PRO","LU2461242641.AUD","LU1983299246.USD"],"gpt_icon":0},{"id":"2577817928","title":"Alterity Therapeutics Announces 2025 Annual General Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2577817928","media":"TIPRANKS","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577817928?lang=en_us&edition=fundamental","pubTime":"2025-10-21 12:17","pubTimestamp":1761020267,"startTime":"0","endTime":"0","summary":"Alterity Therapeutics ( ($AU:ATH) ) has issued an update. Alterity Therapeutics Limited has announced its Annual General Meeting scheduled for Nove...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/alterity-therapeutics-announces-2025-annual-general-meeting?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/alterity-therapeutics-announces-2025-annual-general-meeting?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","BK4007","BK4139","LENZ"],"gpt_icon":0},{"id":"2577819809","title":"PYC Therapeutics Launches Global Repeat Dose Study of Eye Disease Drug Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2577819809","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577819809?lang=en_us&edition=fundamental","pubTime":"2025-10-21 10:11","pubTimestamp":1761012684,"startTime":"0","endTime":"0","summary":"PYC Therapeutics  started a global repeat dose phase 1b study of its PYC-001 drug candidate in patients with autosomal dominant optic atrophy, a genetic eye disease, according to a Tuesday Australian bourse filing.The first patient enrolled in the trial received an initial dose of PYC-001 via intravitreal administration.The study seeks to probe the safety and tolerability profile of PYC-001 and determine the optimal dose and dosing regimen for the drug candidate, per the filing. A secondary objective of the study is to provide preliminary efficacy insights following administration.The study will evaluate three different doses of 10 micrograms per eye, 30 micrograms, and 60 micrograms, as well as two different dose intervals of eight weeks and 12 weeks, the filing said. Each patient enrolled in the study is expected to receive three doses of the drug candidate in a single eye.The firm's shares rose almost 1% in recent trading on Tuesday.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","BK4007","BK7067","BK4539","PYC.AU","BK4139"],"gpt_icon":0},{"id":"2577481606","title":"Major Stakeholder Sells Millions in LAVA Therapeutics Stock!","url":"https://stock-news.laohu8.com/highlight/detail?id=2577481606","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577481606?lang=en_us&edition=fundamental","pubTime":"2025-10-21 10:01","pubTimestamp":1761012119,"startTime":"0","endTime":"0","summary":"New insider activity at LAVA Therapeutics ( ($LVTX) ) has taken place on October 20, 2025. Significant shareholder Cooperatieve Gilde Healthcare IV...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/major-stakeholder-sells-millions-in-lava-therapeutics-stock-insider-trading?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/major-stakeholder-sells-millions-in-lava-therapeutics-stock-insider-trading?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XLV","LVTX","BK4585","BK4588","BK4139","BK4581","LABU","BK4007","LENZ","XBI","BK4539"],"gpt_icon":0},{"id":"2577890119","title":"PYC Therapeutics Launches Global Trial for ADOA Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2577890119","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577890119?lang=en_us&edition=fundamental","pubTime":"2025-10-21 08:17","pubTimestamp":1761005848,"startTime":"0","endTime":"0","summary":"PYC Therapeutics Limited ( ($AU:PYC) ) has issued an update. PYC Therapeutics Limited has initiated a global Phase 1b clinical trial, known as the ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/pyc-therapeutics-launches-global-trial-for-adoa-treatment?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/pyc-therapeutics-launches-global-trial-for-adoa-treatment?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","LENZ","BK4539","BK4139"],"gpt_icon":0},{"id":"2577897400","title":"Arovella Therapeutics Showcases iNKT Cell Therapy at AusBiotech Invest 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2577897400","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577897400?lang=en_us&edition=fundamental","pubTime":"2025-10-21 07:48","pubTimestamp":1761004104,"startTime":"0","endTime":"0","summary":"Arovella Therapeutics Limited ( ($AU:ALA) ) has provided an announcement. Arovella Therapeutics Ltd announced that its CEO, Dr. Michael Baker, will...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/arovella-therapeutics-showcases-inkt-cell-therapy-at-ausbiotech-invest-2025?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/arovella-therapeutics-showcases-inkt-cell-therapy-at-ausbiotech-invest-2025?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4139","BK4539","LENZ"],"gpt_icon":0},{"id":"2577289254","title":"Tryptamine Therapeutics to Present at Microcap Investment Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2577289254","media":"TIPRANKS","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577289254?lang=en_us&edition=fundamental","pubTime":"2025-10-21 07:07","pubTimestamp":1761001635,"startTime":"0","endTime":"0","summary":"Tryptamine Therapeutics ( ($AU:TYP) ) has issued an announcement. Tryptamine Therapeutics Limited announced its participation in the 14th Annual Mi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/tryptamine-therapeutics-to-present-at-microcap-investment-conference?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/tryptamine-therapeutics-to-present-at-microcap-investment-conference?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LENZ","BK4539","BK4007"],"gpt_icon":0},{"id":"2577916418","title":"Neuphoria Therapeutics Ends SAD Program After Trial Failure","url":"https://stock-news.laohu8.com/highlight/detail?id=2577916418","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577916418?lang=en_us&edition=fundamental","pubTime":"2025-10-21 06:19","pubTimestamp":1760998749,"startTime":"0","endTime":"0","summary":"Neuphoria Therapeutics ( ($NEUP) ) has issued an announcement. On October 20, 2025, Neuphoria Therapeutics announced that its AFFIRM-1 Phase 3 tria...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/neuphoria-therapeutics-ends-sad-program-after-trial-failure?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/neuphoria-therapeutics-ends-sad-program-after-trial-failure?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","BK4139","BK4007","LENZ"],"gpt_icon":0},{"id":"2577489167","title":"Pliant Therapeutics Settles Loan with Oxford Finance","url":"https://stock-news.laohu8.com/highlight/detail?id=2577489167","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577489167?lang=en_us&edition=fundamental","pubTime":"2025-10-21 06:11","pubTimestamp":1760998304,"startTime":"0","endTime":"0","summary":"Pliant Therapeutics ( ($PLRX) ) has provided an announcement. On October 14, 2025, Pliant Therapeutics, Inc. completed a voluntary prepayment of $3...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/pliant-therapeutics-settles-loan-with-oxford-finance?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/pliant-therapeutics-settles-loan-with-oxford-finance?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LENZ","PLRX","BK4539","BK4007","OXM","BK4202"],"gpt_icon":0},{"id":"2577899005","title":"Rapt Therapeutics Raised to Overweight From Neutral by JP Morgan","url":"https://stock-news.laohu8.com/highlight/detail?id=2577899005","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577899005?lang=en_us&edition=fundamental","pubTime":"2025-10-21 06:09","pubTimestamp":1760998140,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/RAPT/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 20, 2025 18:09 ET (22:09 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ"],"gpt_icon":0},{"id":"2577899756","title":"Rapt Therapeutics price target raised to $60 from $41 at Clear Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2577899756","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577899756?lang=en_us&edition=fundamental","pubTime":"2025-10-21 05:50","pubTimestamp":1760997011,"startTime":"0","endTime":"0","summary":"Clear Street analyst Kaveri Pohlman raised the firm’s price target on Rapt Therapeutics (RAPT) to $60 from $41 and keeps a Buy rating on the shares...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/rapt-therapeutics-price-target-raised-to-60-from-41-at-clear-street-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/rapt-therapeutics-price-target-raised-to-60-from-41-at-clear-street-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ"],"gpt_icon":0},{"id":"2577932678","title":"Neuphoria Therapeutics Provides Update on AFFIRM-1 Phase 3 Trial Evaluating BNC210 for the Acute Treatment of Social Anxiety Disorder","url":"https://stock-news.laohu8.com/highlight/detail?id=2577932678","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577932678?lang=en_us&edition=fundamental","pubTime":"2025-10-21 04:15","pubTimestamp":1760991300,"startTime":"0","endTime":"0","summary":"AFFIRM-1 trial did not meet primary endpoint or secondary endpoints Company to conduct strategic review of portfolio and business operations BURLINGTON, Mass., Oct.  20, 2025  (GLOBE NEWSWIRE) -- Neup","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/20/3169781/0/en/Neuphoria-Therapeutics-Provides-Update-on-AFFIRM-1-Phase-3-Trial-Evaluating-BNC210-for-the-Acute-Treatment-of-Social-Anxiety-Disorder.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2106854487.HKD","LU1066053197.SGD","MRK","LU1037948897.HKD","LU2461242641.AUD","SG9999002232.USD","LU0070302665.USD","LU0238689110.USD","LU1093756168.USD","LU1162221912.USD","BK4516","IE00BBT3K403.USD","LU0266013472.USD","LU0861579265.USD","SGXZ57979304.SGD","LU1037948541.HKD","BK4534","LU1093756325.SGD","LU1934455194.USD","LU1941712264.USD","SG9999002224.SGD","SG9999015358.SGD","BK4533","BK4139","LU1066051225.USD","LU1934455277.USD","LU2023250843.SGD","SG9999013999.USD","LU1116320901.HKD","BK4588","IE00BFTCPJ56.SGD","LU1917777945.USD","LU1934455863.HKD","PAM","LU1061106388.HKD","LU0965509101.SGD","LU1989772840.SGD","LU1989772923.USD","LENZ","LU1057294990.SGD","LU2361045086.USD","LU1291159041.SGD","IE000M9KFDE8.USD","LU2361044865.SGD","SG9999014575.USD","IE00B1BXHZ80.USD","LU1699723380.USD","LU0208291251.USD","IE00BJJMRZ35.SGD","IE00BSNM7G36.USD"],"gpt_icon":0},{"id":"2577860961","title":"Summit Therapeutics Launches New Phase III Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2577860961","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577860961?lang=en_us&edition=fundamental","pubTime":"2025-10-21 02:49","pubTimestamp":1760986184,"startTime":"0","endTime":"0","summary":"The latest update is out from Summit Therapeutics ( ($SMMT) ). Summit Therapeutics announced significant progress in its ivonescimab development pr...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/summit-therapeutics-launches-new-phase-iii-study?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/summit-therapeutics-launches-new-phase-iii-study?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4134","SMMF","LENZ","BK4211","BK4539","III","BK4139"],"gpt_icon":0},{"id":"2577904860","title":"Viridian Therapeutics Secures $300M Deal with DRI Healthcare","url":"https://stock-news.laohu8.com/highlight/detail?id=2577904860","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577904860?lang=en_us&edition=fundamental","pubTime":"2025-10-21 02:49","pubTimestamp":1760986155,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Viridian Therapeutics ( ($VRDN) ). On October 17, 2025, Viridian Therapeutics entered into a Purchase and Sale ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/viridian-therapeutics-secures-300m-deal-with-dri-healthcare?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/viridian-therapeutics-secures-300m-deal-with-dri-healthcare?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0029874061.USD","XLV","BK4539","LU0154245756.USD","HCSG","BK4007","BK4137","LABU","DRI","BK4585","LU0154245673.USD","BK4504","BK4139","LU0128526141.USD","LENZ","BK4581","BK4209","XBI","BK4588"],"gpt_icon":0},{"id":"2577935860","title":"Adaptimmune Therapeutics to Delist from Nasdaq by October 27","url":"https://stock-news.laohu8.com/highlight/detail?id=2577935860","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577935860?lang=en_us&edition=fundamental","pubTime":"2025-10-21 02:48","pubTimestamp":1760986122,"startTime":"0","endTime":"0","summary":"Adaptimmune Therapeutics ( ($ADAP) ) has provided an update. Adaptimmune Therapeutics announced its decision to voluntarily delist its American Dep...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/adaptimmune-therapeutics-to-delist-from-nasdaq-by-october-27?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/adaptimmune-therapeutics-to-delist-from-nasdaq-by-october-27?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MNQmain","NQmain","LENZ","NVIW.SI","TQQQ","QLD","BK4007","TSYW.SI","USAW.SI","USJW.SI","SQQQ",".IXIC","BK4539","BK4139","QID","PSQ"],"gpt_icon":0}],"pageSize":20,"totalPage":12,"pageCount":10,"totalSize":235,"code":"91000000","status":"200"}]}}